

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.**  
**(深圳市海普瑞藥業集團股份有限公司)**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock code: 9989)**

**POSITIVE PROFIT ALERT**  
**ANNOUNCEMENT ON THE ESTIMATED INCREASE IN PROFIT**  
**FOR THE INTERIM RESULTS OF 2022**

This announcement is made by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “**Company**”) pursuant to the requirements of Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) for the purpose of providing shareholders of the Company (the “**Shareholders**”) and the public with the financial information of the Company. This announcement is also published in accordance with Rule 13.10B of the Listing Rules as it is also published on the Shenzhen Stock Exchange.

The following is the estimated interim results for 2022 of the Company together with its subsidiaries (the “**Group**”). The financial data contained in this results estimate has not been audited and is, except for non-IFRSs (International Financial Reporting Standards) adjusted net profit attributable to shareholders of the listed company or as otherwise indicated, prepared in accordance with the People's Republic of China Accounting Standards for Business Enterprises. Detailed financial information of the Group for the six months ended 30 June, 2022 will be disclosed in the interim results announcement of the Company for the six months ended 30 June, 2022, which is expected to be published on or before 31 August, 2022 in accordance with the Listing Rules.

## I. ESTIMATED RESULTS FOR THE PERIOD

1. Period to which the estimated results apply: From 1 January, 2022 to 30 June, 2022
2. Expected operating results:  Turnaround  Increase compared with the corresponding period  Decrease compared with the corresponding period

Items	1 January, 2022 to 30 June, 2022	Corresponding period of last year
Net profit attributable to shareholders of the listed company	Earnings: RMB473.500 million to RMB542.000 million	Earnings: RMB338.158 million
	Increase as compared with the corresponding period: 40.02% to 60.28%	
Net profit after non-recurring profit or loss	Earnings: RMB456.000 million to RMB524.500 million	Earnings: RMB284.800 million
	Increase as compared with the corresponding period: 60.11% to 84.16%	
Basic earnings per share	Earnings: RMB0.3227 per share to RMB0.3694 per share	Earnings: RMB0.2305 per share

## II. PRELIMINARY AUDIT OF THE ESTIMATED RESULTS

The relevant data of this estimated results has not been audited by the independent auditor of the Company.

## III. REASONS FOR CHANGES IN THE RESULTS

Reasons for changes in the results:

- (1) During the reporting period, the Company's operating income achieved rapid growth. Benefiting from the continuous development of the Company's enoxaparin sodium finished dose in various regions around the world and the stable growth of API business orders, the Company's heparin industry chain business income achieved rapid growth; meanwhile, based on the further growth of orders in hand and the continuous improvement of on-time and successful delivery rate, the Company's CDMO business income maintained a steady and promising growth trend.

- (2) During the reporting period, the profitability of the Company continued to improve. On the one hand, the Company actively promoted the strategy of improving the management and operation efficiency of the global supply chain, and its effective implementation and execution have achieved periodical results; on the other hand, benefiting from the continuous decrease in the price of raw materials in the second half of 2021, taking into account the factors of production and sales cycle, the decrease in purchase price of raw materials resulted in the gradual decrease in sales cost during the reporting period, and the gross profit margin showed rebound, resulting in an improvement in the Company's overall profitability.

#### IV. OTHER RELEVANT INFORMATION

The Company is still in the course of finalizing its consolidated financial results of the Group for the six months ended 30 June, 2022. The information contained in this announcement is only based on the preliminary assessment made by the Board by reference to the Group's unaudited consolidated management accounts and the information currently available to the Board. Such information has neither been confirmed nor audited by the independent auditor of the Company or the audit committee of the Board and may be subject to change. Shareholders and potential investors are advised to refer to the Company's announcement relating to the interim results of the Group for the six months ended 30 June, 2022, which is expected to be published on or before 31 August, 2022. **Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**Shenzhen Hepalink Pharmaceutical Group Co., Ltd.**  
**Li Li**  
*Chairman*

Shenzhen, the PRC  
July 13, 2022

*As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan and Mr. Shan Yu; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Chen Junfa and Mr. Wang Zhaohui.*